Conclusions: Macrophage-derived AnxA1 plays a functional role in modulating hepatic inflammation and fibrogenesis during NASH progression, suggesting the possible use of AnxA1 analogs for therapeutic control of this disease. This evidence concerns the gene ANXA1 and metabolic dysfunction-associated steatohepatitis.